Affiliation:
1. Department of Internal Medicine Adıyaman University School of Medicine Adıyaman Turkey
Abstract
AbstractThe Coronavirus Disease 2019 (COVID‐19), caused by the virus named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2), is a global public health problem in which atypical findings other than the usual fever and respiratory symptoms render early diagnosis and treatment difficult. Cases with atypical clinical and laboratory presentations continue to pose a challenge in the treatment and control of the disease. This case report aims to share our follow‐up and treatment experience in a patient considered to have antithrombin III (ATIII) deficiency based on activated clotting time (ACT) levels unresponsive to heparin who was admitted to intensive care unit due to COVID‐19‐induced cytokine storm associated with extreme D‐dimer elevation (>65,000 μg/L).
Reference13 articles.
1. Antithrombin substitution therapy;Schinzel H;Blood Coagul Fibrinolysis,1998
2. Antithrombin: structure and function;Pratt CW;Semin Hematol,1991
3. Regulation of Tissue Factor Initiated Thrombin Generation by the Stoichiometric Inhibitors Tissue Factor Pathway Inhibitor, Antithrombin-III, and Heparin Cofactor-II
4. Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in baboons;Niessen RWLM;Thrombosis Haemost,1997
5. The In Vitro Effects of Antithrombin III on the Activated Coagulation Time in Patients on Heparin Therapy